Dados B3 › CEBR3 × EQTL3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | CEBR3 | EQTL3 | year |
|---|---|---|---|
| ROE | 18.7% | 6.5% | 2025 |
| ROIC | 26.9% | 9.3% | 2025 |
| ROA | 16.6% | 2.2% | 2025 |
| Gross margin | 43.8% | 26.1% | 2025 |
| EBIT margin | 44.8% | 15.6% | 2025 |
| Net margin | 46.1% | 4.8% | 2025 |
| Net debt/EBITDA | — | 3.90x | no year where both have it |
| Current ratio | 6.68x | 1.49x | 2025 |
| Revenue growth (1y) | 45.7% | 19.0% | 2025 |
| Revenue growth (5y CAGR) | 14.9% | 23.8% | 2025 |
| Piotroski F-Score | 4/9! | 5/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | CEBR3 | EQTL3 | year |
|---|---|---|---|
| P/E | 12.35x | 32.35x | 2025 |
| P/B | 2.51x | 2.11x | 2025 |
| EV/EBITDA | — | 8.72x | 2025 |
| FCF yield | — | -7.6% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:12 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it